PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-36.93
Negative P/E while Drug Manufacturers - Specialty & Generic median is -1.33. Seth Klarman would scrutinize path to profitability versus peers.
36.62
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.29. Jim Chanos would check for potential multiple compression risks.
1.42
P/B 50-90% of Drug Manufacturers - Specialty & Generic median of 1.76. Mohnish Pabrai would examine if this discount presents opportunity.
-56.16
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -11.94. Seth Klarman would investigate cash flow improvement potential.
-65.99
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is -7.19. Seth Klarman would investigate operational improvement potential.
1.42
Fair value ratio 50-90% of Drug Manufacturers - Specialty & Generic median of 1.76. Mohnish Pabrai would examine if this gap presents opportunity.
-0.68%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is -0.17%. Seth Klarman would investigate path to profitability.
-1.78%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.66%. Seth Klarman would investigate cash flow improvement potential.